Trials / Completed
CompletedNCT03839875
Evaluation of Efficacy and Safety of Gynomax® XL Ovule
A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Exeltis Turkey · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this open label, single-arm, multicentral study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gynomax® XL Vaginal Ovule | tioconazole, tinidazole, lidocaine |
Timeline
- Start date
- 2019-04-03
- Primary completion
- 2019-08-09
- Completion
- 2019-08-09
- First posted
- 2019-02-15
- Last updated
- 2020-01-31
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03839875. Inclusion in this directory is not an endorsement.